Skip to main content

CORRECTION article

Front. Oncol., 10 June 2024
Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Corrigendum: Advanced lung cancer inflammation index predicts survival outcomes of hepatocellular carcinoma patients receiving immunotherapy

Qian Li*Qian Li1*Fei MaFei Ma2Ju feng WangJu feng Wang1
  • 1Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
  • 2Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

In the published article, there was an error in affiliation 1. Instead of “Department of Oncology, Zhengzhou University’s Affiliated Cancer Hospital, Henan Cancer Hospital, Zhengzhou, China”, it should be “Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China”.

Furthermore, there was an error in affiliation 2. Instead of “Department of General Surgery, Zhengzhou University’s Affiliated Cancer Hospital, Henan Cancer Hospital, Zhengzhou, China”, it should be “Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China”.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: advanced lung cancer inflammatory index (ALI), hepatocellular carcinoma, Immunotherapy, nomogram, prognosis

Citation: Li Q, Ma F and Wang J (2024) Corrigendum: Advanced lung cancer inflammation index predicts survival outcomes of hepatocellular carcinoma patients receiving immunotherapy. Front. Oncol. 14:1431058. doi: 10.3389/fonc.2024.1431058

Received: 11 May 2024; Accepted: 28 May 2024;
Published: 10 June 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Li, Ma and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Qian Li, zlyyliqian3798@zzu.edu.cn; subbud@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.